Downregulating the canonical wnt/b-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress

Neurochemical Research

Volumn 37, Issue 7, 2012, Pages 1409-1419

  Zhang, Yinghua ^a   Sun, Yan ^a   Wang, Fei ^a   Wang, Zhongping ^a,b   Peng, Yuwen ^a   Li, Ruixi ^a  

^a FUDAN UNIVERSITY   (China)

^b JIUJIANG UNIVERSITY   (China)

Author keywords

Autism; Oxidative stress; Sulindac; Valproic acid; Wnt signaling

Indexed keywords

4 HYDROXYNONENAL; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; SULINDAC; VALPROIC ACID; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; BEHAVIOR DISORDER; COMPULSION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG MECHANISM; FEMALE; LEARNING; LIPID PEROXIDATION; MALE; MEMORY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PAIN THRESHOLD; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOTYPY; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; AUTISTIC DISORDER; BASE SEQUENCE; BEHAVIOR, ANIMAL; BETA CATENIN; DNA PRIMERS; DOWN-REGULATION; FEMALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANIMALIA; RATTUS;

EID: 84862866769     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0724-2     Document Type: Article

References (52)

1. Ciani L, Salinas PC (2005) WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 6:351-362
2. Chenn A, Walsh CA (2002) Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297:365-369
3. Brault V, Moore R, Kutsch S et al (2001) Inactivation of the betacatenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128:1253-1264
4. Atkin TA, MacAskill AF, Brandon NJ et al. (2011) Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons. Mol Psychiatry 16:122-124, 121
5. Clay HB, Sillivan S, Konradi C (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 29:311-324
6. Yao JK, Reddy RD, van DKP (2001) Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310
7. Crespi B, Stead P, Elliot M (2010) Evolution in health and medicine Sackler colloquium: comparative genomics of autism and schizophrenia. Proc Natl Acad Sci USA 107(SUPPL. 1):1736-1741
8. McGinnis WR (2004) Oxidative stress in autism. Altern Ther Health Med 10:22-36; quiz 37, 92
9. Chauhan A, Chauhan V, Brown WT et al (2004) Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci 75:2539-2549
10. James SJ, Cutler P, Melnyk S et al (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80:1611-1617
11. Sajdel-Sulkowska EM, Xu M, McGinnis W et al (2010) Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD). Cerebellum 10:43-48
12. Lee HJ, Wang NX, Shi DL et al (2009) Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. Angew Chem Int Ed Engl 48:6448-6452
13. Stein U, Arlt F, Smith J et al (2011) Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 13:131-144
14. Lu W, Tinsley HN, Keeton A et al (2009) Suppression of Wnt/ beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 602:8-14
15. Cho NL, Lin CI, Whang EE et al (2010) Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. Thyroid 20:615-622
16. Sajdel-Sulkowska EM, Xu M, McGinnis W et al (2011) Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD). Cerebellum 10:43-48
17. Palmieri L, Papaleo V, Porcelli V et al (2010) Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 15:38-52
18. James SJ, Rose S, Melnyk S et al (2009) Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 23:2374-2383
19. Wang Z, Xu L, Zhu X et al (2010) Demethylation of specific Wnt/beta-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure. Anat Rec (Hoboken) 293(11):1947-1953
20. Lemjabbar-Alaoui H, Dasari V, Sidhu SS et al (2006) Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS One 1:e93
21. Huang Y, Chang X, Lee J et al (2011) Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma. Int J Cancer 128:2261-2273
22. Rice PL, Kelloff J, Sullivan H et al (2003) Sulindac metabolites induce caspase-and proteasome-dependent degradation of betacatenin protein in human colon cancer cells. Mol Cancer Ther 2:885-892
23. Orner GA, Dashwood WM, Blum CA et al (2003) Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of betacatenin signaling by a combination of tea plus sulindac. Carcinogenesis 24:263-267
24. Toledo EM, Colombres M, Inestrosa NC (2008) Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86:281-296
25. Schneider T, Przewlocki R (2005) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30:80-89
26. Schneider T, Turczak J, Przewlocki R (2006) Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 31:36-46
27. Stokstad E (2001) Development. New hints into the biological basis of autism. Science 294:34-37
28. Kogan MD, Blumberg SJ, Schieve LA et al (2009) Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124:1395-1403
29. Shattuck PT (2006) The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 117:1028-1037
30. Croen LA, Grether JK, Hoogstrate J et al (2002) The changing prevalence of autism in California. J Autism Dev Disord 32:207-215
31. Blaxill MF, Baskin DS, Spitzer WO (2003) Commentary: Blaxill, Baskin, and Spitzer on Croen et al. (2002), the changing prevalence of autism in California. J Autism Dev Disord 33:223-226; discussion 227-229
32. DiCicco-Bloom E, Lord C, Zwaigenbaum L et al (2006) The developmental neurobiology of autism spectrum disorder. J Neurosci 26:6897-6906
33. Landrigan PJ (2010) What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 22:219-225
34. Evatt ML, DeLong MR, Grant WB et al (2009) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 73:997
35. Bromley RL, Mawer G, Clayton-Smith J et al (2008) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71:1923-1924
36. Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the embryo and fetus. Reprod Toxicol 28:1-10
37. Bambini-Junior V, Rodrigues L, Behr GA et al (2011) Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters. Brain Res 1408:8-16
38. Rasalam AD, Hailey H, Williams JH et al (2005) Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 47:551-555
39. De Ferrari GV, Moon RT (2006) The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25:7545-7553
40. Zhang A, Shen CH, Ma SY et al (2009) Altered expression of autism-associated genes in the brain of fragile X mouse model. Biochem Biophys Res Commun 379:920-923
41. Mines MA, Yuskaitis CJ, King MK et al (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 5:e9706
42. Takahashi-Yanaga F, Shiraishi F, Hirata M et al (2004) Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. Biochem Biophys Res Commun 316: 411-415
43. Wassink TH, Piven J, Vieland VJ et al (2001) Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet 105:406-413
44. Chenn A, Walsh CA (2003) Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb Cortex 13:599-606
45. Villagonzalo KA, Dodd S, Dean O et al (2010) Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets 14:1301-1310
46. Ounjaijean S, Westermarck T, Partinen M et al (2011) Increase in non-transferrin bound iron and the oxidative stress status in epilepsy patients treated using valproic acid monotherapy. Int J Clin Pharmacol Ther 49:268-276
47. Zhang B, Wang X, Nazarali AJ (2010) Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis in mouse embryos in culture. Cell Mol Neurobiol 30:137-148
48. Tung EW, Winn L (2011) Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol 80:979-987
49. Wagner GC, Reuhl KR, Cheh M et al (2006) A new neurobehavioral model of autism in mice: pre-and postnatal exposure to sodium valproate. J Autism Dev Disord 36:779-793
50. Tsujino N, Nakatani Y, Seki Y et al (2007) Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. Neurosci Res 57:289-295
51. Dufour-Rainfray D, Vourc'h P, Le GAM et al (2010) Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett 470:55-59
52. Markram K, Rinaldi T, La Mendola D et al (2008) Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 33:901-912